Summary
When Congress designed the Orphan Drug Act in 1983, lawmakers had a noble goal: to incentivize pharmaceutical companies to develop treatments for rare diseases, those that impact fewer than 200,000 patients, that they wouldnt normally invest in. Four decades later, a budget reconciliation law has c…
Source: Managed Healthcare Executive
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
